The global rise in medical cannabis use has put a spotlight on how this plant is grown, harvested, and prepared. For medical cannabis to be safe and effective, cultivation quality standards must be carefully maintained. This includes following established guidelines known as Good Agricultural and Collection Practice (GACP). In this blog post, we explain what GACP means for cannabis cultivation, who follows these standards, and how it ties into the licensed and unlicensed medical cannabis supply chains in the UK and beyond.
Understanding Good Agricultural and Collection Practice (GACP)
GACP stands for Good Agricultural and Collection Practice. It is a set of principles and standards intended to ensure quality in the cultivation and collection of medicinal plants. The World Health Organization (WHO) first developed GACP guidelines for herbs to support safe and effective herbal medicines. These guidelines have since been adopted internationally and tailored for cannabis, where quality and consistency are crucial.
In the context of medical cannabis, GACP covers all stages of the plant lifecycle from seed or clone selection, cultivation methods, pest control, harvesting techniques, drying, and storage of raw material. The aim is to produce cannabis that is free from contaminants, consistent in potency, and meets safety standards required for medicinal use.
Why GACP is Important for Medical Cannabis Raw Material
- Patient safety: Prevents contamination with harmful chemicals or microbes. Consistency: Controls variability in cannabinoid content and quality, important for both licensed and unlicensed medicines. Compliance: Meets regulatory expectations from agencies such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Traceability: Ensures full accountability in the supply chain.
Without strict adherence to GACP standards, medical cannabis products could fail safety or efficacy tests. This would affect patient access and could lead to regulatory penalties.
Licensed vs Unlicensed Pathways for Medical Cannabis in the UK
The UK’s medical cannabis market is unique and tightly regulated. It operates via two main pathways:
GACP’s Role in Both Pathways
For licensed medicines, cannabis raw material must come from authorised manufacturers who strictly follow GACP and Good Manufacturing Practice (GMP). This ensures the final product maintains consistent quality.
For unlicensed specials, GACP still applies because the raw material must be of pharmaceutical-grade quality. Many manufacturers importing cannabis for specials rely on GACP-certified suppliers to meet the MHRA’s expectations. The agency maintains oversight to assure quality even if the product lacks a UK licence.
Named-Patient Unlicensed Specials and Specialist Prescribing
Most legal medical cannabis prescriptions in the UK are for unlicensed specials prescribed on a named-patient basis. This means a clinician prescribes a product specifically for one patient, often after conventional treatments have failed.
Specialist clinicians – often working in private clinics such as Releaf cannabis clinic – are leading the way in accessing unlicensed cannabis-based medicines. These clinics understand the complexities of unlicensed prescribing and navigate regulatory requirements carefully.
Key considerations for specialist prescribing include:
- Confirming product quality and source using GACP as an assurance metric. Ensuring patient informed consent, describing the unlicensed nature of the medicine. Coordinating with accredited pharmacies to supply bespoke cannabis formulations.
Access Through Private Clinics and NHS Prescribing
Private clinics such as Releaf cannabis clinic offer patients an alternative route to obtain prescriptions. Meanwhile, NHS prescribing remains rare and generally limited to licensed pharmaceuticals or exceptional cases involving specials. The regulatory framework requires tight control of cannabis raw material to ensure patient safety regardless of prescribing pathway.
Authorised Manufacturers and Importers
The UK’s medical cannabis supply chain must carefully control and document every step from seed to patient. This responsibility lies with authorised manufacturers and importers who must comply with several sets of standards:
- GACP: For cultivation and collection of cannabis raw material. GMP (Good Manufacturing Practice): For processes converting raw material into finished medicinal products. MHRA Regulatory Compliance: For licensing, quality control, and pharmacovigilance.
Only companies registered and inspected by the MHRA can legally supply cannabis for medicinal use in the UK. They must demonstrate that their cultivation operations meet GACP standards, establishing robust quality controls and traceable supply chains.
Examples of GACP in Practice
- Seed selection and genetics to ensure consistent cannabinoid profiles. Controlled indoor growing environments to mitigate pests and contaminants. Validated harvesting and drying methods preserving potent active compounds. Laboratory testing of raw material for residual pesticides, heavy metals, mould, and potency.
Monitoring and Staying Informed: Pharma Journal 'Listen' Audio and Site Subscription
For clinicians and professionals interested in staying on top of evolving best practices in medical cannabis, including GACP standards, the Pharma Journal offers valuable resources. Its ‘Listen’ audio option allows busy healthcare providers to absorb updates during commutes or multitasking.
Additionally, subscribing to sites such as medicalcannabis.co.uk provides timely news, regulatory updates, and expert insights on topics like Good Agricultural and Collection Practice. These tools help practitioners, wholesalers, and pharmacists maintain compliant supply chains and optimise patient care.
Summary Table: GACP and Medical Cannabis Supply Chain Stakeholders
Stakeholder Role GACP Relevance Examples Growers & Cultivators Produce raw cannabis material Must comply with GACP standards for cultivation, harvesting, storage Indoor farms, licenced cultivation sites Authorised Manufacturers Process raw material into finished medicinal products Use GACP-grown material; follow GMP for processing UK-licensed cannabis product companies Importers Bring cannabis products or raw material into the UK Source from GACP-certified suppliers; ensure compliance with MHRA Wholesalers registered with MHRA Clinicians & Private Clinics Prescribe cannabis medicines, often unlicensed specials Check product origin and quality; educate patients Releaf cannabis clinic Regulatory Agencies Inspect, license, and monitor supply Set and enforce GACP and GMP standards Medicines and Healthcare products Regulatory Agency (MHRA)Conclusion
Good Agricultural and Collection Practice (GACP) is a cornerstone of cultivating medical cannabis raw material that is safe, consistent, and suitable for pharmaceutical use. In the UK, GACP underpins both licensed and unlicensed pathways, supporting authorised manufacturers, importers, prescribers, and clinics like pharma-journal.com Releaf cannabis clinic. The MHRA ensures these standards are met to protect patient safety and maintain confidence in medical cannabis treatments.
Anyone involved in medical cannabis—from growers to clinicians—must understand and follow GACP guidelines. Staying informed through expert resources such as the Pharma Journal ‘Listen’ audio option and subscribing to dedicated platforms like medicalcannabis.co.uk helps all stakeholders navigate this evolving sector responsibly.
```